4-(Chloromethyl)-2-methylthiophene | 1082602-29-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 4-(Chloromethyl)-2-methylthiophene
• CAS: 1082602-29-6
• 化学式: C₆H₇ClS
• 分子量: 146.64
• InChiKey: PKIGRYNBOCVOIW-UHFFFAOYSA-N

物化性质

• 沸点：
  200.0±25.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Active substance combination for the treatment of diabetes
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1946778A1

  公开（公告）日：2008-07-23

  The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, used to treat diabetes, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种取代吡唑啉化合物和至少一种药物，用于治疗糖尿病，包括该活性物质组合的药物、包括该活性物质组合的制药配方以及利用该活性物质组合制造药物的用途。
• Substituted pyrazoline for preventing weight gain
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1946777A1

  公开（公告）日：2008-07-23

  The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, known to produce weight-gain as a side effect, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种取代吡唑啉化合物和至少一种药物，该药物以体重增加作为副作用而知名，包括所述活性物质组合的药物、包括所述活性物质组合的药物制剂、以及利用所述活性物质组合制造药物。
• Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1743894A1

  公开（公告）日：2007-01-17

  The present invention relates to heterocyclyl-substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及杂环基取代的吡唑啉化合物、其制备方法、包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。
• HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHOD OF USE
  申请人：Gray Jeffrey Lyle

  公开号：US20120077975A1

  公开（公告）日：2012-03-29

  The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

  本公开涉及有效作为人类蛋白酪氨酸磷酸酶β（HPTP-β）抑制剂的化合物，从而调节血管生成。本公开进一步涉及包含所述人类蛋白酪氨酸磷酸酶β（HPTP-β）抑制剂的组合物，以及调节血管生成的方法。
• US8329916B2
  申请人：——

  公开号：US8329916B2

  公开（公告）日：2012-12-11